EE17 A Cost-Utility Analysis of Sparsentan for the Treatment of Immunoglobulin A Nephropathy in the UK
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.403
https://www.valueinhealthjournal.com/article/S1098-3015(25)02960-2/fulltext
Title :
EE17 A Cost-Utility Analysis of Sparsentan for the Treatment of Immunoglobulin A Nephropathy in the UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)02960-2&doi=10.1016/j.jval.2025.09.403
First page :
Section Title :
Open access? :
No
Section Order :
10010